We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Information on semaglutide and compounding.
- Authors
Knopf, Alison
- Abstract
Semaglutide belongs to a class of medications known as glucagon‐like peptide‐1 (GLP‐1) receptor agonists. It mimics the GLP‐1 hormone that is released in the gastrointestinal tract in response to eating. One role of GLP‐1 is to prompt the body to produce more insulin, which reduces blood glucose (sugar). GLP‐1 in higher amounts also interacts with the parts of the brain that reduce appetite and signal a feeling of fullness.
- Subjects
UNITED States; MARKETING laws; GLUCAGON-like peptide-1 agonists; TYPE 1 diabetes; PATIENT education; HEALTH self-care; PEOPLE with diabetes; INVESTIGATIONAL drugs; UNITED States. Food &; Drug Administration; HYPOGLYCEMIC agents; ORAL drug administration; PHARMACY information services; DRUG approval; INJECTIONS; DOSAGE forms of drugs; TYPE 2 diabetes; DRUG counterfeiting; PSYCHOSOCIAL factors
- Publication
Brown University Child & Adolescent Psychopharmacology Update, 2024, Vol 26, Issue 7, p8
- ISSN
1527-8395
- Publication type
Article
- DOI
10.1002/cpu30881